Kymab has developed a proprietary mouse platform which contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies.
Program Areas: Malaria
Genocea harnesses the power of T cells to discover life-changing vaccines and immunotherapies. The foundation partnered with the team to identify antigens for future malaria vaccines as T cell response is critical during the liver-stage of disease.
The foundation invested in Amyris to support the development of new, low-cost technologies for manufacturing compounds to make semi-synthetic artemisinin that can be used in anti-malaria treatments.
Press Release: Kymab secures US $100 million Series C funding
Kymab November 24, 2016 Kymab Group Limited (“Kymab”), a leading monoclonal antibody biopharmaceutical group, announced today that it has successfully secured a US$100 million (£81 million) Series C financing. The financing was led by new investors ORI Healthcare Fund L.P. Read More
Press Release: Genocea announces $1.2 million grant for malaria vaccine discovery
Genocea September 23, 2014 Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the receipt of a $1.2 million grant from the Bill & Melinda Gates Foundation for the identification of protective T cell antigens for malaria Read More